FDA approves Lilly's once-weekly basal insulin Onswik for adults with type 2 diabetes

The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Onswik, a basal insulin designed for once-weekly injection in adults with type 2 diabetes. The new formulation offers patients an alternative to the daily long-acting insulin shots that are currently standard.

Onswik is positioned as a convenience-focused therapy, aiming to improve adherence by reducing injection frequency. Clinical data supporting the approval were not detailed in the brief, but the agency’s decision signals confidence in its safety and efficacy for the indicated population.

In related news, a California federal court jury found Lilly had breached a contract with Nektar Therapeutics over the co-development of an autoimmune drug, awarding Nektar $90 million in damages. The award was lower than Nektar’s request but underscores ongoing legal challenges for the company.